Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants
Part of paid clinical trials in Lincoln, Nebraska.
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Study ID
- NCT04958135
- Phase
- PHASE1
- Status
- Completed
Conditions
- Healthy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- Acoramidis — DRUGFilm-coated immediate release oral tablet.
Study Details
The purpose of this study is to determine the effect of a high-fat, high-caloric meal on the pharmacokinetics (PK) of acoramidis in healthy adult participants following an oral single dose administration of acoramidis. Blood sampling for PK assessment will include measures for acoramidis and its metabolite, acoramidis acyl glucuronide (acoramidis-AG).
Key Dates
- Start date
- May 30, 2021
- Status verified
- Mar 2026
- Primary completion
- Aug 4, 2021
- Completion
- Aug 4, 2021
Study Design
- Enrollment
- 18 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: Sequence 1: AcoramidisParticipants will receive acoramidis once each period as a single dose under fasted or fed conditions as follows: Period 1: Acoramidis as an immediate-release tablet under fasted conditions. Period 2: Acoramidis as an immediate-release tablet under fed conditions. There will be a washout period of at least 14 days between acoramidis dosing.
- Experimental: Sequence 2: AcoramidisParticipants will receive acoramidis once each period as a single dose under fasted or fed conditions as follows: Period 1: Acoramidis as an immediate-release tablet under fed conditions. Period 2: Acoramidis as an immediate-release tablet under fasted conditions. There will be a washout period of at least 14 days between acoramidis dosing.
Primary Outcome Measure
Maximum Observed Plasma Concentration (Cmax) Of Acoramidis: Fed (Test) Versus Fasted (Reference) Conditions [ Time Frame: Up to 336 hours postdose ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Celerion | Lincoln | Nebraska | 68502 | - |
Find similar trials in Lincoln, NE
By research site
Related Studies
- A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).PHASE1 · Recruiting · Merck Sharp & Dohme LLC · Glendale, California
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their BabiesPHASE3 · Recruiting · Pfizer · Birmingham, Alabama
- A Phase 1 Study of BLKR201 in Healthy Adult ParticipantsPHASE1 · Recruiting · Formation Bio, Inc. · Lincoln, Nebraska
- Study of New Magnetic Resonance Imaging Methods of the BrainRecruiting · National Institute of Neurological Disorders and Stroke (NINDS) · Bethesda, Maryland